# ACAD catalysts: ACADIA PHARMACEUTICALS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/acad/catalysts

> ACADIA PHARMACEUTICALS INC (ACAD) has 10 upcoming catalysts. The next is the ACP-211 primary completion, August 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ACADIA PHARMACEUTICALS INC |
| Ticker | ACAD (Nasdaq) |
| SEC CIK | 1070494 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/acad |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2023 | [DAYBUE (trofinetide) FDA approval](https://sec-api.dev/pdufa/trofinetide) | ACAD | Rett syndrome | completed, approved | "In March 2023, the FDA approved the Company's second drug, DAYBUE® (trofinetide), for the treatment of Rett syndrome." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070494/000119312526447794/acad-20260930.htm)) |
| Nov 2023 | [Remlifanserin trial start](https://sec-api.dev/pdufa/remlifanserin) | ACAD | hallucinations and delusions associated with ADP | completed | "In November 2023, we initiated a Phase 2 study evaluating the efficacy and safety of remlifanserin for the treatment of hallucinations and delusions associated with ADP." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)) |
| Mar 2024 | [NUPLAZID (pimavanserin) topline data readout](https://sec-api.dev/pdufa/pimavanserin) | ACAD | negative symptoms of schizophrenia | completed, negative | "In March 2024 we reported top-line results from a Phase 3 study of pimavanserin for the treatment of the negative symptoms of schizophrenia." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)) |
| February 26, 2025 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000095017025027759/acad-ex99_1.htm)) |
| May 7, 2025 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/acad-ex99_1.htm)) |
| Q3 2025 | [Remlifanserin trial start](https://sec-api.dev/pdufa/remlifanserin) | ACAD |  | scheduled | "In January, the Company announced plans for the initiation of a Phase 2 study of ACP-204 for a second indication in Lewy Body Dementia Psychosis in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000095017025027759/acad-ex99_1.htm)) |
| August 6, 2025 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000095017025104092/acad-ex99_1.htm)) |
| August 19, 2025 | [Carbetocin primary completion](https://sec-api.dev/pdufa/carbetocin) | ACAD | Hyperphagia in Prader-Willi Syndrome | completed | "NCT06173531 (Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-19 (ACTUAL); Lead Sponsor ACADIA Pharmaceuticals Inc.; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06173531)) |
| Q4 2025 | [ACP-101 topline data readout](https://sec-api.dev/pdufa/acp-101) | ACAD |  | scheduled | "We expect to report top-line results from this study early in the fourth quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070494/000095017025104295/acad-20250630.htm)) |
| November 5, 2025 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312525266959/acad-ex99_1.htm)) |
| Dec 2025 | [DAYBUE (trofinetide) FDA approval](https://sec-api.dev/pdufa/trofinetide) | ACAD | Rett syndrome | completed, approved | "The FDA approved DAYBUE STIX in December 2025 for the treatment of Rett syndrome and we made the product available on a limited basis in the first quarter of 2026 followed by a broader launch in the second quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070494/000119312526447794/acad-20260930.htm)) |
| December 19, 2025 | [Carbetocin primary completion](https://sec-api.dev/pdufa/carbetocin) | ACAD | Hyperphagia in Prader-Willi Syndrome | withdrawn | "NCT06420297 (OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06420297)) |
| 2026 | [Fintepla (fenfluramine) trial start](https://sec-api.dev/pdufa/fenfluramine) | ACAD | Rett syndrome during 2026 | scheduled | "UCB S.A. has announced plans to initiate a Phase 3 clinical trial of fenfluramine in patients with Rett syndrome during 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)) |
| Q1 2026 | [ACP-101 NDA/BLA submission](https://sec-api.dev/pdufa/acp-101) | ACAD |  | scheduled | "If results are positive, the Company anticipates submitting a New Drug Application to the U.S. Food and Drug Administration in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/acad-ex99_1.htm)) |
| February 25, 2026 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526071674/acad-ex99_1.htm)) |
| mid-2026 | [ACADIA PHARMACEUTICALS INC topline data readout](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | scheduled | "We expect to complete enrollment in the Phase 2 RADIANT study in the first quarter of 2026 and subsequently report top-line results around mid-2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070494/000095017025029253/acad-20241231.htm)) |
| May 6, 2026 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-ex99_1.htm)) |
| August 4, 2026 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-ex99_1.htm)) |
| September 11, 2026 | [ACADIA PHARMACEUTICALS INC complete response letter (CRL)](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed, complete response letter | "And, on April 5, 2021, Acadia announced that the FDA had issued a Complete Response Letter ("CRL"), stating that it could not approve the sNDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428dex991.htm)) |
| Oct 2026 | [ACADIA PHARMACEUTICALS INC topline data readout](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | scheduled | "We have completed enrollment in the Phase 2 portion of the RADIANT program, initiated screening and enrollment in the Phase 3 portion and expect topline results for the Phase 2 portion between September and October 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm)) |
| Oct 2026 | [Remlifanserin topline data readout](https://sec-api.dev/pdufa/remlifanserin) | ACAD |  | scheduled | "- Topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis anticipated September to October 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-ex99_1.htm)) |
| Q4 2026 | [ACP-711 trial start](https://sec-api.dev/pdufa/acp-711) | ACAD | CNS disorders and rare diseases | scheduled | "In the fourth quarter of 2026, we plan to initiate a Phase 2 study of ACP-711 in essential tremor." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)) |
| Q4 2026 | [ACADIA PHARMACEUTICALS INC topline data readout](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | scheduled | "We expect to report top-line results from this Phase 3 trial either in the fourth quarter of 2026 or in the first quarter of 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)) |
| October 15, 2026 | [Carbetocin topline data readout](https://sec-api.dev/pdufa/carbetocin) | ACAD | Hyperphagia in Prader-Willi Syndrome | completed | "NCT06173531 (Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-19 (ACTUAL); Lead Sponsor ACADIA Pharmaceuticals Inc.; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06173531?tab=results)) |
| Nov 2026 | [DAYBUE (trofinetide) topline data readout](https://sec-api.dev/pdufa/trofinetide) | ACAD |  | scheduled | "Accelerated enrollment in the trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026 timeframe." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-ex99_1.htm)) |
| November 4, 2026 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526447276/acad-ex99_1.htm)) |
| August 2027 | [ACP-211 primary completion](https://sec-api.dev/pdufa/acp-211) | ACAD | Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant | scheduled | "NCT07284667 (ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284667)) |
| Aug to Nov 2027 | [ACP-211 topline data readout](https://sec-api.dev/pdufa/acp-211) | ACAD | Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant | scheduled | "NCT07284667 (ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284667)) |
| January 2028 | [ACP-204 primary completion](https://sec-api.dev/pdufa/acp-204) | ACAD | Alzheimer's Disease Psychosis | scheduled | "NCT06159673 (ACP-204 in Adults With Alzheimer's Disease Psychosis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06159673)) |
| Jan to Apr 2028 | [ACP-204 topline data readout](https://sec-api.dev/pdufa/acp-204) | ACAD | Alzheimer's Disease Psychosis | scheduled | "NCT06159673 (ACP-204 in Adults With Alzheimer's Disease Psychosis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06159673)) |
| February 2028 | [ACP-204 primary completion](https://sec-api.dev/pdufa/acp-204) | ACAD | Lewy Body Dementia Psychosis | scheduled | "NCT07029581 (Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029581)) |
| Feb to May 2028 | [ACP-204 topline data readout](https://sec-api.dev/pdufa/acp-204) | ACAD | Lewy Body Dementia Psychosis | scheduled | "NCT07029581 (Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029581)) |
| February 2029 | [ACP-204 primary completion](https://sec-api.dev/pdufa/acp-204) | ACAD | Lewy Body Dementia Psychosis | scheduled | "NCT07095465 (Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07095465)) |
| Feb to May 2029 | [ACP-204 topline data readout](https://sec-api.dev/pdufa/acp-204) | ACAD | Lewy Body Dementia Psychosis | scheduled | "NCT07095465 (Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07095465)) |
| April 2029 | [ACP-204 primary completion](https://sec-api.dev/pdufa/acp-204) | ACAD | Alzheimer's Disease Psychosis | scheduled | "NCT06194799 (ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06194799)) |
| Apr to Jul 2029 | [ACP-204 topline data readout](https://sec-api.dev/pdufa/acp-204) | ACAD | Alzheimer's Disease Psychosis | scheduled | "NCT06194799 (ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06194799)) |

## Drugs

- [ACP-101](https://sec-api.dev/pdufa/acp-101): 
- [ACP-204](https://sec-api.dev/pdufa/acp-204): Alzheimer's Disease Psychosis, Lewy Body Dementia Psychosis
- [ACP-211](https://sec-api.dev/pdufa/acp-211): major depressive disorder, Major Depressive Disorder (MDD)
- [ACP-711](https://sec-api.dev/pdufa/acp-711): cns disorders and rare diseases, essential tremor
- [Carbetocin](https://sec-api.dev/pdufa/carbetocin): Hyperphagia in Prader-Willi Syndrome
- [Fintepla (fenfluramine)](https://sec-api.dev/pdufa/fenfluramine): rett syndrome during 2026
- [NUPLAZID (pimavanserin)](https://sec-api.dev/pdufa/pimavanserin): negative symptoms of schizophrenia
- [Remlifanserin](https://sec-api.dev/pdufa/remlifanserin): hallucinations and delusions associated with adp
- [DAYBUE (trofinetide)](https://sec-api.dev/pdufa/trofinetide): rett syndrome, rett syndrome in adult and pediatric patients two years of age and older

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/acad/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ACAD catalysts: ACADIA PHARMACEUTICALS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/acad/catalysts

```bibtex
@misc{secapidev_companies_acad_catalysts_20261116,
  title        = {ACAD catalysts: ACADIA PHARMACEUTICALS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/acad/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_acad_catalysts_20261116","title":"ACAD catalysts: ACADIA PHARMACEUTICALS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/acad/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
